vs
百利高（PRGO）与Ubiquiti Inc.（UI）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是Ubiquiti Inc.的1.4倍（$1.1B vs $814.9M），Ubiquiti Inc.净利率更高（28.7% vs -127.8%，领先156.5%），Ubiquiti Inc.同比增速更快（35.8% vs -2.5%），Ubiquiti Inc.自由现金流更多（$260.3M vs $148.6M），过去两年Ubiquiti Inc.的营收复合增速更高（28.6% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
Ubiquiti Inc.是一家美国科技企业，2003年于加利福尼亚州圣何塞成立，目前总部位于纽约。公司旗下拥有多个品牌，主营面向企业及家庭用户的有线、无线数据通信产品的研发、生产与销售。
PRGO vs UI — 直观对比
营收规模更大
PRGO
是对方的1.4倍
$814.9M
营收增速更快
UI
高出38.4%
-2.5%
净利率更高
UI
高出156.5%
-127.8%
自由现金流更多
UI
多$111.7M
$148.6M
两年增速更快
UI
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $814.9M |
| 净利润 | $-1.4B | $233.6M |
| 毛利率 | 32.6% | 45.9% |
| 营业利润率 | -116.0% | 35.9% |
| 净利率 | -127.8% | 28.7% |
| 营收同比 | -2.5% | 35.8% |
| 净利润同比 | -3093.9% | 70.8% |
| 每股收益（稀释后） | $-10.23 | $3.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGOUI
| Q4 25 | $1.1B | $814.9M | ||
| Q3 25 | $1.0B | $733.8M | ||
| Q2 25 | $1.1B | $759.2M | ||
| Q1 25 | $1.0B | $664.2M | ||
| Q4 24 | $1.1B | $599.9M | ||
| Q3 24 | $1.1B | $550.3M | ||
| Q2 24 | $1.1B | $507.5M | ||
| Q1 24 | $1.1B | $493.0M |
净利润PRGOUI
| Q4 25 | $-1.4B | $233.6M | ||
| Q3 25 | $7.5M | $207.9M | ||
| Q2 25 | $-8.4M | $266.7M | ||
| Q1 25 | $-6.4M | $180.4M | ||
| Q4 24 | $-44.4M | $136.8M | ||
| Q3 24 | $-21.0M | $128.0M | ||
| Q2 24 | $-108.4M | $103.8M | ||
| Q1 24 | $2.0M | $76.3M |
毛利率PRGOUI
| Q4 25 | 32.6% | 45.9% | ||
| Q3 25 | 36.1% | 46.0% | ||
| Q2 25 | 34.4% | 45.1% | ||
| Q1 25 | 37.6% | 44.5% | ||
| Q4 24 | 33.9% | 41.2% | ||
| Q3 24 | 37.2% | 42.1% | ||
| Q2 24 | 37.0% | 40.2% | ||
| Q1 24 | 33.1% | 35.3% |
营业利润率PRGOUI
| Q4 25 | -116.0% | 35.9% | ||
| Q3 25 | 7.0% | 35.7% | ||
| Q2 25 | 4.3% | 34.4% | ||
| Q1 25 | 4.5% | 34.2% | ||
| Q4 24 | 10.0% | 29.8% | ||
| Q3 24 | 7.4% | 30.7% | ||
| Q2 24 | -2.5% | 27.3% | ||
| Q1 24 | -5.1% | 22.6% |
净利率PRGOUI
| Q4 25 | -127.8% | 28.7% | ||
| Q3 25 | 0.7% | 28.3% | ||
| Q2 25 | -0.8% | 35.1% | ||
| Q1 25 | -0.6% | 27.2% | ||
| Q4 24 | -3.9% | 22.8% | ||
| Q3 24 | -1.9% | 23.3% | ||
| Q2 24 | -10.2% | 20.5% | ||
| Q1 24 | 0.2% | 15.5% |
每股收益（稀释后）PRGOUI
| Q4 25 | $-10.23 | $3.86 | ||
| Q3 25 | $0.05 | $3.43 | ||
| Q2 25 | $-0.06 | $4.40 | ||
| Q1 25 | $-0.05 | $2.98 | ||
| Q4 24 | $-0.32 | $2.26 | ||
| Q3 24 | $-0.15 | $2.12 | ||
| Q2 24 | $-0.79 | $1.72 | ||
| Q1 24 | $0.01 | $1.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $302.8M |
| 总债务越低越好 | — | $47.5M |
| 股东权益账面价值 | $2.9B | $1.0B |
| 总资产 | $8.5B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 0.05× |
8季度趋势，按日历期对齐
现金及短期投资PRGOUI
| Q4 25 | — | $302.8M | ||
| Q3 25 | $432.1M | $177.2M | ||
| Q2 25 | $454.2M | $149.7M | ||
| Q1 25 | $409.9M | $151.0M | ||
| Q4 24 | $558.8M | $133.1M | ||
| Q3 24 | $1.5B | $165.2M | ||
| Q2 24 | $542.8M | $126.3M | ||
| Q1 24 | $658.5M | $102.5M |
总债务PRGOUI
| Q4 25 | — | $47.5M | ||
| Q3 25 | — | $133.8M | ||
| Q2 25 | — | $250.0M | ||
| Q1 25 | — | $340.0M | ||
| Q4 24 | — | $406.3M | ||
| Q3 24 | — | $552.5M | ||
| Q2 24 | — | $708.1M | ||
| Q1 24 | — | $877.5M |
股东权益PRGOUI
| Q4 25 | $2.9B | $1.0B | ||
| Q3 25 | $4.4B | $828.4M | ||
| Q2 25 | $4.5B | $668.3M | ||
| Q1 25 | $4.4B | $436.1M | ||
| Q4 24 | $4.3B | $290.4M | ||
| Q3 24 | $4.6B | $188.1M | ||
| Q2 24 | $4.5B | $95.1M | ||
| Q1 24 | $4.7B | $25.9M |
总资产PRGOUI
| Q4 25 | $8.5B | $1.6B | ||
| Q3 25 | $10.1B | $1.5B | ||
| Q2 25 | $10.1B | $1.5B | ||
| Q1 25 | $9.8B | $1.3B | ||
| Q4 24 | $9.6B | $1.2B | ||
| Q3 24 | $11.2B | $1.2B | ||
| Q2 24 | $10.4B | $1.2B | ||
| Q1 24 | $10.6B | $1.2B |
负债/权益比PRGOUI
| Q4 25 | — | 0.05× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.37× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 7.45× | ||
| Q1 24 | — | 33.92× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $263.9M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $260.3M |
| 自由现金流率自由现金流/营收 | 13.4% | 31.9% |
| 资本支出强度资本支出/营收 | 2.4% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 1.13× |
| 过去12个月自由现金流最近4个季度 | $145.1M | $699.5M |
8季度趋势，按日历期对齐
经营现金流PRGOUI
| Q4 25 | $175.4M | $263.9M | ||
| Q3 25 | $51.7M | $198.5M | ||
| Q2 25 | $75.9M | $130.4M | ||
| Q1 25 | $-64.5M | $123.6M | ||
| Q4 24 | $312.6M | $152.4M | ||
| Q3 24 | $42.2M | $233.7M | ||
| Q2 24 | $9.5M | $231.4M | ||
| Q1 24 | $-1.4M | $163.9M |
自由现金流PRGOUI
| Q4 25 | $148.6M | $260.3M | ||
| Q3 25 | $29.8M | $193.3M | ||
| Q2 25 | $56.7M | $125.2M | ||
| Q1 25 | $-90.0M | $120.7M | ||
| Q4 24 | $274.9M | $150.4M | ||
| Q3 24 | $15.1M | $231.1M | ||
| Q2 24 | $-18.9M | $229.5M | ||
| Q1 24 | $-26.5M | $160.6M |
自由现金流率PRGOUI
| Q4 25 | 13.4% | 31.9% | ||
| Q3 25 | 2.9% | 26.3% | ||
| Q2 25 | 5.4% | 16.5% | ||
| Q1 25 | -8.6% | 18.2% | ||
| Q4 24 | 24.2% | 25.1% | ||
| Q3 24 | 1.4% | 42.0% | ||
| Q2 24 | -1.8% | 45.2% | ||
| Q1 24 | -2.4% | 32.6% |
资本支出强度PRGOUI
| Q4 25 | 2.4% | 0.4% | ||
| Q3 25 | 2.1% | 0.7% | ||
| Q2 25 | 1.8% | 0.7% | ||
| Q1 25 | 2.4% | 0.4% | ||
| Q4 24 | 3.3% | 0.3% | ||
| Q3 24 | 2.5% | 0.5% | ||
| Q2 24 | 2.7% | 0.4% | ||
| Q1 24 | 2.3% | 0.7% |
现金转化率PRGOUI
| Q4 25 | — | 1.13× | ||
| Q3 25 | 6.89× | 0.95× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.68× | ||
| Q4 24 | — | 1.11× | ||
| Q3 24 | — | 1.83× | ||
| Q2 24 | — | 2.23× | ||
| Q1 24 | -0.70× | 2.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
UI
| Enterprise Technology | $729.0M | 89% |
| Service Provider Technology | $85.9M | 11% |
